Tirzepatide vs Semaglutide: Choosing Dual vs Single Pathway Options
A clinic-facing comparison of PureVital Tirzepatide and Semaglutide — mechanisms, presentations, and how teams decide between them.
8 min read · Updated 2026-04-10 · PureVital Learn
Both Semaglutide and Tirzepatide appear in modern weight and metabolic programs, but they are not interchangeable molecules. Semaglutide primarily engages GLP-1 pathways. Tirzepatide is positioned as a dual GIP/GLP-1 agonist — often considered when a clinician wants broader incretin coverage.
When clinics lean Semaglutide
- Established protocols and staff familiarity already exist
- Patients need flexible forms (vial, pen, capsule, drops)
- A stepwise GLP-1 start is preferred before dual-agonist escalation
- Oral Chromium-supported capsules are part of the adherence plan
When clinics lean Tirzepatide
- Dual-pathway therapy is clinically preferred after assessment
- Patient history suggests a need to change molecule class rather than escalate Semaglutide alone
- Inventory can support vial, pen, and drop continuity for the same molecule
PureVital Tirzepatide detail
PureVital lists Tirzepatide 45 mg / 3 ml vial (Total API 135 mg), a matching pen, and Tirzepatide Sublingual Drops at 5 mg per ml (30 ml, Total API 150 mg). High Total API figures help clinics plan inventory for multi-visit programs.
- Review comorbidities, medications, and prior incretin exposure
- Confirm patient preference for injectable vs needle-free routes
- Map strength/API to titration length and follow-up visits
- Stock at least one backup form to protect adherence
Compare these PureVital SKUs
Semaglutide
7.92mg/ 3ml · Vial · API 23.76 mg
$179.99
Tirzepatide
45mg /3ml · Vial · API 135 mg
$299.99
Semaglutide Pen
7.92mg /3ml · Pen · API 23.76 mg
$239.99
Tirzepatide Pen
45mg/ 3ml · Pen · API 135 mg
$383.99
Semaglutide Sublingual Drops
25 mg per ml (30mls) · Drops · API 750 mg
$117.99
Tirzepatide Sublingual Drops
5 mg per ml (30mls) · Drops · API 150 mg
$143.99